

This listing of claims will replace all prior versions, and listings, of claims in this application:

Listing of Claims:

Claims 1-76 (canceled)

Claim 77 (previously presented): The antibody, or an antigen binding fragment thereof, of claim 84, wherein said antibody is a humanized antibody.

Claim 78 (previously presented): The antibody, or an antigen binding fragment thereof, of claim 84, wherein said antibody is a chimeric antibody.

Claim 79 (canceled)

Claim 80 (previously presented): The antibody, or antigen binding fragment thereof, of claim 84, wherein said antibody, or antigen binding fragment thereof, is identified by screening a phage display library with a modified integrin polypeptide, and isolating said antibody, or antigen binding fragment thereof.

Claims 81-83 (canceled)

Claim 84 (currently amended): An antibody, or an antigen binding fragment thereof, which binds to an integrin I-domain of SEQ ID NO:2 ~~an α L-integrin~~, the I-domain being locked in the open conformation by the substitutions E284C/E301C or K287C/K294C but not to a modified integrin I-domain that is locked in the closed conformation by the substitutions L289C/K294C ~~K289C/K294C~~.

Claim 85 (canceled)

Claim 86 (canceled)

Claim 87 (previously presented): The antibody, or antigen binding fragment thereof, of claim 84,

wherein the I-domain in the open conformation comprises substitutions E284C/E301C in an α L subunit.

Claim 88 (previously presented): The antibody, or antigen binding fragment thereof, of claim 84, wherein the I-domain in the open conformation comprises substitutions K287C/K294C in an α L subunit.

Claims 89-104 (canceled)

Claims 105 (previously presented): The antibody, or antigen binding fragment thereof, of claim 84 that is a monoclonal antibody.

Claims 106 (previously presented): The antibody, or antigen binding fragment thereof, of claim 84 that is a recombinant antibody.

Claims 107-113 (canceled)

Claim 114 (previously presented): The antibody, or antigen binding fragment, of claim 84 further comprising a physically linked detectable substance.

Claim 115 (previously presented): The antibody, or antigen binding fragment, of claim 114, wherein the physically linked detectable substance comprises an enzyme, a fluorescent material, or a radioactive material.

Claims 116-127 (canceled)

Claim 128 (previously presented): A pharmaceutical composition comprising (i) an antibody or antigen binding fragment thereof according to claim 84, and (ii) a pharmaceutically acceptable carrier.

Claims 129-132 (canceled)

Claim 133 (previously presented): A recombinant antibody, or an antigen binding fragment thereof, which binds to an integrin I-domain of SEQ ID NO:2 ~~an α L-integrin~~, the I-domain being locked in

the open conformation by the substitutions E284C/E301C but not to a modified α L integrin I-domain that is locked in the closed conformation by the substitutions L289C/K294C~~K289C/K294C~~, wherein the antibody or antigen binding fragment thereof blocks interaction between LFA-1 and ICAM-1.

Claim 134 (previously presented): A recombinant antibody, or an antigen binding fragment thereof, which binds to an integrin I-domain of SEQ ID NO:2 ~~an α L integrin~~, the I-domain being locked in the open conformation by the substitutions K287C/K294C-but not to a modified α L integrin I-domain that is locked in the closed conformation by the substitutions L289C/K294C~~K289C/K294C~~, wherein the antibody or antigen binding fragment thereof blocks interaction between LFA-1 and ICAM-1.